Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Apalutamide does not affect health-related quality of life in patients with localized prostate cancer

Posted by on Nov 28, 2018 in Prostate cancer | 0 comments

In a nutshell This study investigated the effect of apalutamide (Erleada) on health-related quality of life (H-QoL) in patients with prostate cancer. This study found that apalutimide preserved H-QoL while prolonging time taken for cancer to spread.  Some background One treatment option for patients with prostate cancer is androgen...

Read More

Is conventional or hypofractionated radiation therapy better for the treatment of prostate cancer?

Posted by on Nov 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study compared two different types of radiation therapy after prostate surgery for prostate cancer, hypofractionated postprostatectomy radiation therapy (hypoPORT) and conventional postprostatectomy radiation therapy (coPORT). Results showed that hypoPORT may be effective in prostate cancer control and with similar side effects as...

Read More

Evaluating optimal duration of androgen deprivation therapy in high risk prostate cancer

Posted by on Nov 25, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the effect of the length of androgen deprivation therapy (ADT) when used with radiotherapy in patients with prostate cancer. This study found that 18 months ADT led to similar overall survival and better quality of life as compared to 36 months in these patients.  Some background...

Read More

Comparing two hormone therapy drugs in men with advanced, non-metastatic prostate cancer

Posted by on Nov 17, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...

Read More

Evaluating long-term outcomes of stereotactic body radiation therapy for low- and medium-risk prostate cancer

Posted by on Nov 13, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of stereotactic body radiation therapy (SBRT) as a treatment for prostate cancer. This study found that SBRT is a safe and effective option for low and medium risk prostate cancer. Some background Stereotactic body radiotherapy (SBRT) is a treatment option for...

Read More

Evaluating stereotactic ablative body radiotherapy treatment option for low volume advanced prostate cancer

Posted by on Nov 10, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of stereotactic ablative body radiotherapy (SABR) used as a treatment in low volume metastatic (spread) prostate cancer. This study found that SABR is effective and has few side-effects. Some background Stereotactic ablative body radiotherapy (SABR) is a treatment option...

Read More

Guidelines for hypofractionated radiation therapy for localized prostate cancer

Posted by on Nov 10, 2018 in Prostate cancer | 0 comments

In a nutshell This study reviewed the current recommendations for treatment doses of radiation therapy for different stages of prostate cancer.  Some background Hypo-fractionated radiation therapy (HFRT) for early-stage prostate cancer is a safe and effective treatment option. It involves a shorter course of treatment with larger doses...

Read More

Comparing prostate surgery with radiotherapy and radiotherapy with androgen deprivation therapy for advanced prostate cancer

Posted by on Oct 28, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the long-term effects of two treatment combinations for advanced prostate cancer. This study found that surgery and radiotherapy had improved overall survival in comparison with radiotherapy plus androgen deprivation therapy (ADT) in these patients, but with higher rates of side-effects. Some background...

Read More

External beam radiotherapy increases the risk of bladder cancer in patients with prostate cancer

Posted by on Oct 27, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the risks of bladder or rectal cancer for patients who have had surgery or external beam radiotherapy (EBRT) as a treatment for prostate cancer. This study found that radiation therapy led to a higher risk of bladder cancer, as compared to prostate surgery.  Some background Surgery and radiation...

Read More

Better survival for patients with new metastatic prostate cancer with previous prostate surgery

Posted by on Oct 19, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the effect previous treatment has on overall survival for patients with metastatic (spread) prostate cancer. This study found that patients who had previous prostate surgery and radiation had improved overall survival.  Some background Localized prostate cancer can be treated using prostate-removing...

Read More

Can prednisone be replaced with dexamethasone in patients with prostate cancer treated with abiraterone acetate?

Posted by on Sep 29, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the use of dexamethasone, instead of prednisone, used with abiraterone acetate (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC). This study found that prednisone to dexamethasone switch can benefit some patients with mCRPC. Some background Androgen deprivation therapy...

Read More